(Q34001569)

English

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

phase I clinical trial

0 references

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Ramesh K Ramanathan

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Joe J Stephenson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Glen J Weiss

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Linda A Pestano

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Ann Lowe

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Alton Hiscox

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Rafael A Leos

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Lynn Kirkpatrick

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Donald A Richards

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

24 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1591-1596

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21863237%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Thioredoxin signaling as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Thioredoxin, a regulator of gene expression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Hypoxia, clonal selection, and the role of HIF-1 in tumor progression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Extracellular thioredoxin levels are increased in patients with acute lung injury.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Elevated circulating levels of thioredoxin and stress in chronic heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Changes in thioredoxin concentrations: an observation in an ultra-marathon race

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

HIF-1alpha and cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9739-9

21 January 2018

The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21863237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thioredoxin blood level increases after severe burn injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/21863237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21863237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21863237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21863237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

1 reference

https://pubmed.ncbi.nlm.nih.gov/21863237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34001569&oldid=2196103685"